A Phase 1 Dose Escalation and Expansion Study of XB628 as a Single Agent and in Combination With Zanzalintinib in Participants With Advanced or Metastatic Solid Tumors
Exelixis
Summary
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Key Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. * Minimum life expectancy of ≥ 12 weeks. * Have a recurrent advanced or metastatic solid tumor that is histologically or cytologically confirmed. * Adequate organ and marrow function. * Not amenable to curative treatment with surgery or radiation. * Received at least 1 line of prior systemic anticancer therapy in the recurrent or metastatic setting. * Acceptable alternative therapy was received, refused, intolerable, or no longer effective. * Capable of understanding and complying with the protoc…
Interventions
- BiologicalXB628
Intravenous infusion(s)
- DrugZanzalintinib
Oral tablet(s)
Locations (11)
- Exelixis Clinical Site #5San Francisco, California
- Exelixis Clinical Site #4New Haven, Connecticut
- Exelixis Clinical Site #8Tampa, Florida
- Exelixis Clinical Site #10Boston, Massachusetts
- Exelixis Clinical Site #11Boston, Massachusetts
- Exelixis Clinical Site #6St Louis, Missouri